Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes

Reuters

2025/11/04

Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes

Bio-Techne Corporation, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580273083"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580273083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580273083?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580273083","market":"fut","top_or_hot":-1,"title":"Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a>, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-04 22:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a>, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z6F94.USD","symbol_name":"Legg Mason Royce - US Smaller Companies A Acc USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL3YPfZf:1","article_id":"2580273083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580273083","pubTimestamp":1762264968,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bio-Techne Corporation, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer  2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.Disclaimer: This news brief was created by Public Technologies  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4121":"生命科学工具和服务","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4585":"ETF&股票定投概念","BK4588":"碎股","TECH":"Techne Corporation"},"translate_title":"Bio-Techne公布人工智能驱动的空间生物学数据预测黑色素瘤免疫治疗结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":0.9},"content_text":"Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n    \n\n        Bio-Techne Corporation, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}